Orbital pseudotumor (idiopathic orbital inflammation/IOI) is a non-specific, non-granulomatous, non-neoplastic orbital inflammatory disease and is the most common cause of orbital masses after thyroid ophthalmopathy. It presents acutely or subacutely with painful proptosis, restricted eye movement, and periorbital swelling. It can involve any orbital structure: extraocular muscles (myositis), lacrimal gland (dacryoadenitis), orbital fat, optic nerve sheath (perineuritis), or sclera (scleritis). It may present in diffuse or focal forms. Although etiology is unknown, autoimmune mechanisms are considered. Diagnosis is usually made through clinical-radiological correlation and dramatic response to steroid therapy — however, differentiation from lymphoma is critical and biopsy may be required. Bilateral involvement should raise suspicion for IgG4-related disease or systemic inflammatory disease.
Age Range
20-60
Peak Age
40
Gender
Equal
Prevalence
Uncommon
The pathophysiology of orbital pseudotumor is not fully understood, but autoimmune mechanisms are believed to play a role. Histologically, it is characterized by polymorphic lymphocytic infiltration, plasma cells, histiocytes, and variable degrees of fibrosis. Inflammatory infiltration causes edema and volume increase in involved orbital structures — reflected as mass effect and enhancement on CT/MRI. Unlike thyroid ophthalmopathy, tendon insertion sites of muscles can also be involved ('tendon involvement') because the inflammatory process is not directed at a specific cell type — non-selective inflammation affects all tissue components. In lacrimal gland involvement, lymphocytic infiltration of gland parenchyma leads to glandular enlargement and increased enhancement. While edema is dominant in the acute phase, fibrosis becomes predominant in the chronic phase and treatment response decreases. Steroid response is explained by induction of apoptosis of inflammatory cells and reduction of vascular permeability — creating dramatic clinical and imaging improvement.
The most distinguishing finding of extraocular muscle involvement in orbital pseudotumor is that muscle thickening includes the tendon insertion site (T-sign). While tendons are spared in thyroid ophthalmopathy, non-selective inflammation in pseudotumor affects all muscle components including tendons. Coronal CT/MRI shows thickening continuing from the thickened muscle belly to the scleral insertion. This finding is the most reliable imaging criterion in the differential diagnosis of these two diseases and guides diagnosis together with clinical evaluation. The triad of tendon involvement with painful proptosis and steroid response strongly supports pseudotumor.
On T2-weighted sequences, orbital pseudotumor generally shows intermediate or slightly low signal — resulting from cellular inflammatory infiltration and fibrosis component shortening T2 relaxation time. This is distinctly different from the bright T2 signal of cavernous venous malformation. In the acute phase with edema dominance, more hyperintense signal is seen; in the chronic phase with fibrosis dominance, more hypointense signal. Infiltrative pattern appears as blurred margins around involved structures and diffuse fat infiltration. Active inflammation areas show hyperintense signal on STIR sequences.
Report Sentence
An infiltrative pattern soft tissue mass showing intermediate signal on T2-weighted sequences is identified in the orbital region.
On contrast-enhanced MRI, involved orbital structures show intense and diffuse enhancement. In muscle involvement, both muscle belly and tendon enhance — tendon enhancement is a critical finding for differentiation from thyroid ophthalmopathy. In lacrimal gland involvement, the gland enhances homogeneously and intensely. In the diffuse form, widespread enhancement due to orbital fat infiltration is seen. In the focal form, well-defined or poorly defined focal mass enhancement is seen. Enhancement amount correlates with disease activity — post-treatment enhancement decrease indicates response.
Report Sentence
On contrast-enhanced series, intense diffuse enhancement is identified in involved orbital structures with enhancement also present at the tendon insertion site in extraocular muscle involvement.
On contrast-enhanced CT, diffuse or focal orbital mass shows intense enhancement. In the diffuse form, increased retrobulbar fat density (fat stranding), extraocular muscle thickening, and lacrimal gland enlargement are seen. In the focal form, a well or poorly defined enhancing mass is seen — the lacrimal gland is the most common site of focal involvement. In muscle involvement, both muscle belly and tendon insertion site are thickened — a critical CT finding differentiating from thyroid ophthalmopathy. Bone destruction is not expected — helpful in differentiation from malignant tumors. Extension to orbital apex indicates optic nerve compression risk.
Report Sentence
Contrast-enhanced CT demonstrates a diffusely enhancing infiltrative soft tissue mass in the orbital region accompanied by increased orbital fat density and retrobulbar fat stranding.
B-mode ultrasonography demonstrates hypoechoic, irregularly marginated, infiltrative mass or thickening in involved orbital structures. In extraocular muscle involvement, muscle thickness is increased and echogenicity decreased — reflecting edema content. In lacrimal gland involvement, the gland is enlarged and hypoechoic. T-sign (tendon involvement): continuation of thickening at the muscle-tendon junction can be demonstrated. Low internal reflectivity on A-mode ultrasonography indicates active inflammation. Retrobulbar fat infiltration is seen as echogenicity changes in fat.
Report Sentence
Ultrasonography demonstrates increased extraocular muscle thickness with decreased echogenicity, with thickening continuing at the muscle-tendon junction.
On diffusion-weighted imaging, orbital pseudotumor generally does not show marked restricted diffusion or shows mild restriction. ADC values are in the intermediate range — higher than lymphoma, lower than normal tissue. This DWI finding plays an important role in differentiation from orbital lymphoma: lymphoma shows marked restricted diffusion and low ADC values due to high cellularity, while pseudotumor shows intermediate ADC with more heterogeneous cellularity and edema content. In the chronic fibrotic phase, ADC values may increase further.
Report Sentence
The lesion does not show marked restricted diffusion on diffusion-weighted imaging with intermediate ADC values — a finding inconsistent with lymphoma.
Criteria
Extraocular muscle involvement dominant — muscle thickening, tendon involvement, painful eye movement.
Distinct Features
Differentiated from thyroid ophthalmopathy by tendon involvement. Generally unilateral, single muscle involvement possible. Lateral rectus is most commonly involved (least involved in thyroid ophthalmopathy).
Criteria
Lacrimal gland involvement dominant — superolateral orbital mass, eyelid swelling, palpable mass. Lacrimal gland enlarged, enhancing, diffuse or focal.
Distinct Features
Differentiation from lacrimal gland lymphoma, pleomorphic adenoma, adenoid cystic carcinoma is needed. Biopsy is frequently indicated. Steroid response supports pseudotumor but partial response may also occur in lymphoma.
Criteria
Simultaneous involvement of multiple orbital structures — muscles, fat, lacrimal gland, nerve sheath. Diffuse orbital fat infiltration is dominant. Severe proptosis and restricted eye movement.
Distinct Features
Most severe form — highest optic neuropathy risk. Requires aggressive steroid treatment and follow-up. Differentiation from orbital lymphoma and metastasis is critical — biopsy threshold should be low.
Distinguishing Feature
Orbital lymphoma shows marked restricted diffusion and low ADC (<1.0 × 10⁻³ mm²/s) on DWI — intermediate ADC in pseudotumor. Lymphoma wraps structures with 'moulding' effect, has slower onset and pain is generally mild. Steroid response is dramatic in pseudotumor, may be partial in lymphoma. Biopsy required for definitive diagnosis.
Distinguishing Feature
Thyroid ophthalmopathy shows bilateral, tendon-sparing muscle thickening (I'M SLow pattern). Pseudotumor is generally unilateral with tendon involvement. Pain is minimal in thyroid ophthalmopathy, prominent in pseudotumor. Thyroid function tests and TRAb help differentiation.
Distinguishing Feature
IgG4-related disease shows bilateral lacrimal gland enlargement, infraorbital nerve thickening and systemic involvement (pancreas, salivary glands). Elevated serum IgG4 is diagnostic clue. Pseudotumor is generally unilateral with isolated orbital involvement. IgG4-positive plasma cells on biopsy provide definitive differentiation.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
Systemic corticosteroids (1 mg/kg/day prednisone) first-line. Dramatic response within 24-48 hours supports diagnosis. Steroid-sparing immunosuppression (methotrexate, mycophenolate) for recurrence. Biopsy for atypical cases, steroid-refractory cases, or lymphoma exclusion. Radiation therapy for recurrent/refractory disease.Systemic corticosteroids (prednisone 1 mg/kg/day) are first-line in orbital pseudotumor treatment, and dramatic clinical and imaging response within 24-48 hours supports the diagnosis. Steroid treatment is continued with dose tapering over 4-6 weeks — early cessation increases recurrence risk. Recurrence rate is 25-50%, and steroid-sparing immunosuppressants (methotrexate, mycophenolate mofetil, azathioprine) are used as second-line therapy. Biopsy indications: atypical presentation, steroid non-response, lymphoma suspicion, bilateral involvement, recurrence. Radiation therapy is an alternative in refractory cases. Emergency high-dose IV methylprednisolone is administered when optic nerve involvement is present. Important distinctions: (1) Lymphoma may partially respond to steroids — response does not exclude lymphoma, (2) Bilateral involvement suggests IgG4-related disease — serum IgG4 and biopsy needed, (3) Bilateral IOI in children requires systemic vasculitis screening.
Dramatic response to steroid therapy supports the diagnosis. Biopsy may be needed to exclude lymphoma. Chronic cases develop fibrosis with diminished steroid response. Alternative treatments: radiotherapy, methotrexate.